一分钟看懂
这是一项关于食管癌的II 期研究，登记的药物或干预包括anlotinib + PD-1 inhibitor；PD-1 inhibitor，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
anlotinib + PD-1 inhibitor；PD-1 inhibitor · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Sun Yat-sen University · 广州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Pathologically confirmed esophageal squamous cell carcinoma;
- 2. Unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma that has not received prior systemic therapy, or recurrence more than 6 months after completion of (neo)adjuvant/radical therapy;
- 3. Patients who have completed 4-6 cycles of PD-1 inhibitor combined with platinum-based doublet chemotherapy, who may receive local therapy if the investigator determines a benefit from local treatment, and who have not progressed after the above treatment;
- 4. Enrollment window: randomization must be performed within 42 days after completion of the last treatment (including local therapy);
- 5. Expected survival greater than 3 months;
- 6. Age 18-75 years;
- 7. ECOG performance status score of 0-1;
- 8. Laboratory tests within 7 days before the first dose must meet the following requirements: Hematology: neutrophils ≥1.5×10\^9/L, platelets ≥75.0×10\^9/L, hemoglobin ≥80 g/L; Liver function: total bilirubin ≤1.5 × ULN, ALT/AST ≤2.5 × ULN (≤5 × ULN if liver metastasis is present); Renal function: serum creatinine ≤1.5 × ULN or creatinine clearance \>60 mL/min; Coagulation function: international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN; no concomitant severe organic disease;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07863141；登记信息更新于 2026-10-07；本站同步于 2026-10-07，中国中心当前名额未经人工确认。